Welcome from the Congress Chairs / Treatment of ovarian cancer in 2023 Educational session

How to select the best first line maintenance treatment? Is molecular profiling the only criteria to choose?

Lecture Time
08:50 - 09:05
Speakers
  • Isabelle L. Ray-Coquard (Lyon, France)
Room
Auditorium 113
Date
Thu, 23.02.2023
Time
08:25 - 09:50
Welcome from the Congress Chairs / Treatment of ovarian cancer in 2023 Educational session

Welcome to the ESMO Gynaecological Cancers Congress 2023

Lecture Time
08:25 - 08:30
Speakers
  • The Chairs (Barcelona, Spain)
Room
Auditorium 113
Date
Thu, 23.02.2023
Time
08:25 - 09:50
Welcome from the Congress Chairs / Treatment of ovarian cancer in 2023 Educational session

New treatment in the current ovarian cancer beyond ADCs

Lecture Time
09:05 - 09:20
Speakers
  • Nicoletta Colombo (Milan, Italy)
Room
Auditorium 113
Date
Thu, 23.02.2023
Time
08:25 - 09:50
Welcome from the Congress Chairs / Treatment of ovarian cancer in 2023 Educational session

PARP inhibitors: Mechanism of resistance and how to overcome

Lecture Time
09:20 - 09:35
Speakers
  • Iain McNeish (London, United Kingdom)
Room
Auditorium 113
Date
Thu, 23.02.2023
Time
08:25 - 09:50
Welcome from the Congress Chairs / Treatment of ovarian cancer in 2023 Educational session

Q&A

Lecture Time
09:35 - 09:50
Speakers
  • All Speakers (Barcelona, Spain)
Room
Auditorium 113
Date
Thu, 23.02.2023
Time
08:25 - 09:50
Welcome from the Congress Chairs / Treatment of ovarian cancer in 2023 Educational session

Introduction

Lecture Time
08:30 - 08:35
Speakers
  • Susana Banerjee (London, United Kingdom)
Room
Auditorium 113
Date
Thu, 23.02.2023
Time
08:25 - 09:50
Welcome from the Congress Chairs / Treatment of ovarian cancer in 2023 Educational session

Do we still need radical surgery in the PARP inhibitor era?

Lecture Time
08:35 - 08:50
Speakers
  • GIOVANNI Scambia (Rome, Italy)
Room
Auditorium 113
Date
Thu, 23.02.2023
Time
08:25 - 09:50
How to interpret overall survival data with PARP inhibitors Special Symposium

Why are we having this Symposium? Recent regulatory actions by FDA/EMEA regarding late-stage approval for PARPi in recurrent ovarian cancer

Lecture Time
10:15 - 10:30
Speakers
  • Robert L. Coleman (The Woodlands, TX, United States of America)
Room
Auditorium 113
Date
Thu, 23.02.2023
Time
10:15 - 11:35
How to interpret overall survival data with PARP inhibitors Special Symposium

Is there clinical evidence to support the link between PARPi use and a negative impact on OS?

Lecture Time
10:30 - 10:45
Speakers
  • Jonathan A. Ledermann (London, United Kingdom)
Room
Auditorium 113
Date
Thu, 23.02.2023
Time
10:15 - 11:35
How to interpret overall survival data with PARP inhibitors Special Symposium

Is there a biological rationale to support decremental impact on overall survival?

Lecture Time
10:45 - 11:00
Speakers
  • Antonio Jose Gonzalez Martin (Madrid, Spain)
Room
Auditorium 113
Date
Thu, 23.02.2023
Time
10:15 - 11:35
How to interpret overall survival data with PARP inhibitors Special Symposium

Q&A

Lecture Time
11:15 - 11:50
Speakers
  • All Speakers (Barcelona, Spain)
Room
Auditorium 113
Date
Thu, 23.02.2023
Time
10:15 - 11:35
Proffered Paper session Proffered Paper session

Invited Discussant of abstract 35O

Lecture Time
12:32 - 12:37
Speakers
  • Jonathan A. Ledermann (London, United Kingdom)
Room
Auditorium 113
Date
Thu, 23.02.2023
Time
11:45 - 12:45